IRIS UniCatt

Innocenti, Idanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.898
EU - Europa 2.405
AS - Asia 1.429
SA - Sud America 139
AF - Africa 33
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 6.909
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.866
SE - Svezia 617
SG - Singapore 574
CN - Cina 499
IT - Italia 448
DE - Germania 438
IE - Irlanda 179
FR - Francia 176
UA - Ucraina 133
IN - India 123
ID - Indonesia 115
BR - Brasile 113
GB - Regno Unito 93
RU - Federazione Russa 73
FI - Finlandia 71
PL - Polonia 53
CI - Costa d'Avorio 26
AT - Austria 25
HK - Hong Kong 25
CA - Canada 24
TR - Turchia 24
BE - Belgio 19
NL - Olanda 15
JP - Giappone 14
CZ - Repubblica Ceca 13
ES - Italia 10
IR - Iran 10
CH - Svizzera 7
IL - Israele 7
MX - Messico 7
CO - Colombia 5
VN - Vietnam 5
AR - Argentina 4
GR - Grecia 4
HU - Ungheria 4
KR - Corea 4
LK - Sri Lanka 4
LT - Lituania 4
RO - Romania 4
UZ - Uzbekistan 4
VE - Venezuela 4
A2 - ???statistics.table.value.countryCode.A2??? 3
CL - Cile 3
EC - Ecuador 3
EG - Egitto 3
PK - Pakistan 3
PT - Portogallo 3
BA - Bosnia-Erzegovina 2
BD - Bangladesh 2
BG - Bulgaria 2
BO - Bolivia 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
PE - Perù 2
PH - Filippine 2
PY - Paraguay 2
QA - Qatar 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AU - Australia 1
BH - Bahrain 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
IQ - Iraq 1
KE - Kenya 1
LV - Lettonia 1
MC - Monaco 1
MD - Moldavia 1
MN - Mongolia 1
MT - Malta 1
OM - Oman 1
SA - Arabia Saudita 1
SI - Slovenia 1
TN - Tunisia 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 6.909
Salva come PNG Salva come JPEG
Città #
Chandler 675
Singapore 336
Ashburn 213
Dublin 176
Jakarta 115
Dearborn 112
San Mateo 103
Jacksonville 101
Beijing 96
Wilmington 95
Ann Arbor 93
Cattolica 76
Rome 74
Nanjing 73
Hyderabad 70
Boston 64
New York 63
Florence 62
Princeton 62
Marseille 61
Milan 58
Fairfield 55
Warsaw 53
Moscow 50
Woodbridge 49
Houston 46
Lancaster 44
Nanchang 39
Los Angeles 38
Munich 38
Bremen 36
Seattle 36
Lawrence 30
Helsinki 29
Frankfurt am Main 28
Abidjan 26
Kunming 26
Redwood City 25
Shenyang 23
Hong Kong 22
Boardman 21
Cambridge 20
Brussels 19
Chicago 17
Düsseldorf 17
Redmond 17
Albany 16
Izmir 16
Minneapolis 16
Vienna 16
Hefei 15
Lauterbourg 15
Norwalk 15
Pune 15
Shanghai 15
Nürnberg 14
Zhengzhou 14
Auburn Hills 13
Mountain View 13
Washington 13
Hebei 12
Nuremberg 12
Tianjin 12
Toronto 12
Jiaxing 11
London 11
Changsha 9
Guangzhou 9
Kyoto 9
Lappeenranta 8
Alzate Brianza 7
Brno 7
Leawood 7
Paris 7
San Francisco 7
São Paulo 7
Augusta 6
Detroit 6
Hangzhou 6
Lanzhou 6
Pellezzano 6
Phoenix 6
Portsmouth 6
Santa Clara 6
Stockholm 6
Chengdu 5
Falkenstein 5
Fremont 5
Jinan 5
Naples 5
Newark 5
North Hollywood 5
Ottawa 5
Vancouver 5
Wuhan 5
Amsterdam 4
Brdo 4
Budapest 4
Colombo 4
Edinburgh 4
Totale 4.059
Salva come PNG Salva come JPEG
Nome #
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 288
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome 157
Docosahexaenoic acid reverts resistance to UV-induced apoptosis in human keratinocytes: involvement of COX-2 and HuR 145
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 143
Docosahexaenoic acid reverts resistance to UV-induced apoptosis in human keratinocytes: involvement of COX-2 and HuR. 125
Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab. 125
Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients 125
New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia 114
Chemoprevention of lung pathologies by dietary n-3 polyunsaturated fatty acids. 111
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia 111
revalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. 111
Docosahexaenoic acid reverts resistance to UV-induced apoptosis in human keratinocytes: involvement of COX-2 and HuR. 104
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 104
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 100
Mycosis fungoides as a cause of severe obstructive sleep apnea 98
Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study 98
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 96
Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units 93
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 89
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia 88
The effects of omega-3 polyunsaturated fatty acids against cancer 85
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 84
Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia 81
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 81
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 78
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 76
Unrelated cord blood transplantation and post-transplant cyclophosphamide 74
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics 74
Chronic Lymphocitic Leukaemia: Census of Patients Treated in Italian Haematology Units 72
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. 71
SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation 70
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 68
the concomitance of lymphoma and breast carcinoma in the bone 67
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. 66
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 66
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 66
Unrelated cord blood transplantation and post-transplant cyclophosphamide 65
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab 64
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 64
Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia 64
Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients 63
Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients 63
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 61
Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax 61
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199 60
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome 60
Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience 60
Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia 59
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 58
B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation 58
Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role 57
Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region 57
VEGF and IL-6 Correlation in POEMS: A Potential Upcoming Marker of Active Disease and Early Autologous BMT Response 57
Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia 57
Chlorambucil PLUS Rituximab As FRONT-LINE THERAPY in Elderly or Unfit Patients Affected by B-CELL Chronic Lymphocytic Leukemia: Results of A Single-Centre Retrospective Analysis 56
CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression 55
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation 53
The concomitance of lymphoma and breast carcinoma in the bone 51
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 51
Treatment options for elderly/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: A comprehensive review 51
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 50
Second haploidentical stem cell transplantation for primary graft failure 50
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 49
Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients 48
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases 48
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 48
New developments in the management of chronic lymphocytic leukemia: role of ofatumumab 47
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience 47
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: A comprehensive review 47
Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia 46
Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role 45
Genetic dynamics in untreated CLL patients with either stable or progressive disease: A longitudinal study 45
Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units 45
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 44
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 44
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. 44
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 44
What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study 43
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 43
Validation of the CLL-IPI and comparison with the MDACC prognostic index: analysis of 1364 newly diagnosed patients 43
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 43
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia 43
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 42
Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia 42
Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience 42
New developments in the management of chronic lymphocytic leukemia: Role of ofatumumab 41
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 41
Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience 41
Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia 40
Extending long term follow up of patient with acute myeloid leukemia after autologous stem cell transplantation: Disclosing late mortality and causes of death 39
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 37
Richter transformation in Chronic Lymphocytic Leukemia 36
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort 36
Enhanced expression of mir-181b in b cells of cll improves the anti-tumor cytotoxic t cell response 36
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab 35
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 34
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study 33
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 32
Combined Genetic Lesions in TP53 and CDKN2A/CDKN2B Drive B Cell Receptor-Dependent/Costimulatory Signal-Independent Proliferation in Richter Syndrome 32
Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis 29
Totale 6.683
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.579
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.579
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020132 0 0 0 0 0 0 0 0 0 0 84 48
2020/2021397 25 41 16 25 79 33 25 11 42 17 75 8
2021/2022771 61 27 31 38 57 14 9 116 32 40 183 163
2022/20231.881 258 253 134 265 145 241 108 140 211 43 64 19
2023/20241.021 45 272 63 64 42 149 70 34 18 43 106 115
2024/20251.300 50 69 146 78 181 69 67 88 274 263 15 0
Totale 7.080